MapLight Therapeutics
MapLight Therapeutics, Inc.
MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for debilitating brain disorders. The company focuses on discovering and developing targeted therapies that precisely address the underlying neural circuits responsible for conditions like schizophrenia and Alzheimer's disease psychosis. Its approach combines innovative science with a proprietary discovery platform to create more effective and safer medications.
Products & Team
ML-007C-MA
ML-007C-MA is an oral, fixed-dose combination therapy representing MapLight's lead clinical candidate. It consists of ML-007, a potent M1/M4 muscarinic agonist designed to activate key receptors in the brain, and a peripherally acting anticholinergic (PAC) compound. This dual-component formulation is engineered to deliver therapeutic effects for psychosis while preventing common side effects that occur outside the central nervous system.
It addresses the critical need for more effective antipsychotic treatments that have a better safety and tolerability profile, potentially improving patient adherence and outcomes for severe conditions like schizophrenia.
The core problem addressed is the lack of safe and effective circuit-specific treatments for complex brain disorders, with many existing therapies causing significant side effects that limit their utility and patient compliance.